NVO: 6-K company filing

6-K 1 f6k_080426.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 4, 2026 NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé 1 DK- 2880, Bagsvaerd Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☒ Form 40-F ☐ Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026 Bagsværd, Denmark, 4 August 2026 – Novo Nordisk today announced adjusted sales and adjusted operating profit for the second quarter of 2026 and raised 2026 full-year adjusted sales and adjusted operating profit outlook at CER. Adjusted sales and adjusted operating profit for the second quarter of 2026 Q2 2026 adjusted sales increased by 7% at CER, and adjusted operating profit increased by 11% at CER. Profit and loss DKK million Q2 2026 Growth at CER Adjusted sales 1 78,488 7 % Adjusted operating profit 1, 2 33,389 11 % CER: Constant exchange rates; 1 Adjusted sales and adjusted operating profit growth rates exclude the non-recurring impact from the provision reversals related to the 340B Drug Pricing Program in the US. 2 Excl. DKK 6.3 billion non-recurring, non-cash impairment charges in Q2 2026 related to intangible pipeline assets, including monlunabant (DKK 4.0 billion) 2026 adjusted sales and adjusted operating profit outlook at CER Adjusted sales growth for 2026 is now expected to be 0% to -6% at CER and adjusted operating profit growth is now expected to be 0% to -6% at CER. The improved outlook is driven by increased expectations for GLP-1 product sales. Ou